OnCore Login

Return to Trial Database

HCRN-GU22-598

Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder

Status

Currently Enrolling

Cancer Type(s)

Bladder

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-GU22-598 being conducted in.
Icahn School of Medicine at Mount Sinai
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278